MONOPROST SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

LATANOPROST

থেকে পাওয়া:

LABORATOIRES THEA

এটিসি কোড:

S01EE01

INN (আন্তর্জাতিক নাম):

LATANOPROST

ডোজ:

50MCG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

LATANOPROST 50MCG

প্রশাসন রুট:

OPHTHALMIC

প্যাকেজ ইউনিট:

0.2ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

PROSTAGLANDIN ANALOGS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0132916001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2016-07-07

পণ্য বৈশিষ্ট্য

_MONOPROST® Product Monograph _
_Page 1 of 30_
PRODUCT MONOGRAPH
INCLUDING CONSUMER INFORMATION
Pr
MONOPROST
®
Latanoprost Ophthalmic Solution
50 µg/mL
(Sterile, preservative-free, single-dose container)
Prostaglandin F
2α
analogue
LABORATOIRES THEA
12 Rue Louis Bleriot
63017 Clermont-Ferrand Cedex 2
France
Date of Preparation:
July 6, 2016
Imported and distributed by :
Labtician Ophthalmics Inc.
2140 Winston Park Drive, Unit 6
Oakville, Ontario, L6H-5V5
Canada
Submission Control No: 173577
_MONOPROST® Product Monograph _
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 11
STORAGE AND STABILITY
.........................................................................................
12
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
.........................................................................
14
CLINICAL TRIALS
................................................................